All In Biotech

Drug Trial Radar · NCT04140526

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)

Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

733

Planned (sponsor's estimate)

Start

Sep 16, 2020

Primary completion

Dec 31, 2026

Study completion Dec 31, 2027

Sponsor

Lead sponsor
OncoC4, Inc.Industry
Sponsor type
Industry
Collaborators
National Cancer Institute (NCI)
First posted
Oct 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancers.

Conditions

  • Non Small Cell Lung Cancer
  • Advanced Solid Tumor
  • Metastatic Melanoma
  • Metastatic Head and Neck Carcinoma
  • Metastatic Renal Cell Carcinoma
  • Metastatic Colorectal Cancer
  • Sarcomas
  • Metastatic Prostate Cancer
  • Ovarian Cancer
  • Small Cell Lung Cancer
  • Metastatic Breast Cancer
  • Pancreas Cancer
  • Gastric Cancer
  • Esophageal Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Cervical Cancer
  • Adenoid Cystic Carcinoma
  • Salivary Gland Cancer
  • Urothelial Carcinoma

Interventions

  • ONC-392Drug

    ONC-392 will be given by intravenous infusion, once every 21 days (Q3W). In Part C Arm M and in Part D, ONC-392 will be given Q4W.

  • PembrolizumabDrug

    Pembrolizumab will be given intravenous (IV) infusion at 200 mg/cycle, once every 21 days (Q3W).

  • DocetaxelDrug

    Docetaxel will be given intravenous (IV) infusion at 75 mg/m2, once every 21 days (Q3W).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT) in monotherapyTime frame: 21 days
  2. Maximal tolerable dose (MTD) in monotherapyTime frame: 21 days
  3. Recommended Phase II Dose (RP2D)Time frame: 21 days
  4. Rate of treatment related adverse events (TRAE) according to CTCAE v5.0Time frame: One year

Locations

37 sites in 2 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Springdale, Arkansas

  • University of California at Davis

    Davis, California

  • The Oncology Institute of Hope and Innovation

    Downey, California

  • City of Hope Cancer Center

    Duarte, California

  • University of Colorado Hospital

    Aurora, Colorado

  • Nuvance Health

    Norwalk, Connecticut

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Florida Cancer Specialists

    Atlantis, Florida

  • University of Florida Health Cancer Center

    Gainesville, Florida

  • Ocala Oncology Florida Cancer Affiliates

    Ocala, Florida

  • AdventHealth Cancer Institute

    Orlando, Florida

  • Memorial Cancer Institute

    Pembroke Pines, Florida

  • Emory University Winship Cancer Institute

    Atlanta, Georgia

  • Norton Health

    Lexington, Kentucky

  • Greater Baltimore Medical Center

    Baltimore, Maryland

  • The Center for Cancer and Blood Disorders

    Bethesda, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Michigan Medical Center

    Ann Arbor, Michigan

  • Atlantic Healthcare System

    Morristown, New Jersey

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • The Ohio State University James Cancer Center

    Columbus, Ohio

  • Zangmeister Cancer Center

    Columbus, Ohio

  • Pennsylvania Cancer Specialists & Research Institute (Formerly Gettysburg Cancer Center)

    Gettysburg, Pennsylvania

  • Prisma Health

    Greenville, South Carolina

  • Tennessee Oncology Chattanooga Memorial Plaza

    Chattanooga, Tennessee

  • Tennessee Oncology - Nashville

    Nashville, Tennessee

  • Houston Methodist Cancer Center

    Houston, Texas

  • Oncology Consultants

    Houston, Texas

  • University of Utah Huntsman Cancer Institute

    Salt Lake City, Utah

  • NEXT/Virginia Cancer Specialists

    Fairfax, Virginia

  • University of Washington / Fred Hutchinson Cancer Center

    Seattle, Washington

  • Newcastle Private Hospital

    New Lambton Heights, New South Wales, Australia

  • Tasman Oncology Research

    Southport, Queensland, Australia

  • Cancer Research SA

    Adelaide, South Australia, Australia

  • Southern Oncology Clinical Research Unit

    Bedford Park, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.